RE: Down, But Not Out (2)12 Apr 2022 19:09
Aether
You enquired if I asked any questions outside of the Sprinter trial and the answer is no. I only pursued Sprinter protocol as it was the best use of a £2,000 or so treatment drug per patient where the result could be a normalised life expectancy. (For example 4 healthy years by giving a treatment equates to £500 a year in the health economics argument). The point to consider in other trials is whether the health economics still stack up.
Tony